本页面由Tiger Trade Technology Pte. Ltd.提供服务

Oyster Point Pharma

11.17
0.0000
成交量:- -
成交额:2,331.11万
市值:3.03亿
市盈率:-1.68
高:11.17
开:11.17
低:11.17
收:11.17
52周最高:18.30
52周最低:3.46
股本:2,714.48万
流通股本:893.31万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-6.6407
每股收益(LYR):-3.8661
净资产收益率:-306.38%
总资产收益率:-65.11%
市净率:-13.66
市盈率(LYR):-2.89

数据加载中...

2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/01/13

重要事件披露

8-K/A [Amend] - Current report
2023/01/13

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/09

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/05

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/03

交易所摘牌声明

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2023/01/03

重要事件披露

8-K - Current report
2023/01/03

员工持股计划

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/01/03

员工持股计划

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/01/03

员工持股计划

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/01/03

员工持股计划

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2022/12/21

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/11/21

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/11/10

重要事件披露

8-K - Current report
2022/11/10

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/11/08

重要事件披露

8-K - Current report
2022/11/07

重要事件披露

8-K - Current report
2022/08/11

重要事件披露

8-K - Current report